Table 2.
Tumor characteristics.
| Characteristics | Number | % |
|---|---|---|
| Pathology | ||
| IDC | 232 | 94.30% |
| ILC | 5 | 2.05% |
| Mucinous | 5 | 2.05% |
| Others | 4 | 1.60% |
| Clinical T stage | ||
| T1 | 46 | 18.70% |
| T2 | 139 | 56.50% |
| T3 | 34 | 13.80% |
| T4 | 27 | 11.00% |
| Clinical N stage | ||
| N0 | 58 | 23.60% |
| N1 | 98 | 39.80% |
| N2 | 49 | 19.90% |
| N3 | 41 | 16.70% |
| Stage | ||
| I | 9 | 3.70% |
| II | 123 | 50.00% |
| III | 114 | 46.30% |
| Operation | ||
| Breast-conserving surgery | 129 | 52.40% |
| Modified radical mastectomy | 117 | 47.60% |
| RT modality | ||
| 3D CRT | 57 | 23.20% |
| IMRT | 189 | 76.80% |
| Dose scheme | ||
| 180 cGy per fraction | 226 | 91.90% |
| 200 cGy per fraction | 8 | 3.20% |
| 267 cGy per fraction | 12 | 4.90% |
| ER | ||
| Negative | 99 | 40.20% |
| Positive | 147 | 59.80% |
| PR | ||
| Negative | 171 | 69.50% |
| Positive | 75 | 30.50% |
| HER2 | ||
| Negative | 170 | 69.10% |
| Positive | 76 | 30.90% |
| Ki-67 | ||
| <15 | 112 | 45.50% |
| ≥15 | 78 | 31.70% |
| Unknown | 56 | 22.80% |
| Chemotherapy regimen | ||
| Adriamycin based | 5 | 2.00% |
| Adriamycin and taxol based | 161 | 65.40% |
| Taxol based | 8 | 3.30% |
| Trastuzumab based | 72 | 29.30% |
| Selective estrogen receptor modulator | ||
| No | 143 | 58.10% |
| Yes | 103 | 41.90% |
| Aromatase inhibitor | ||
| No | 220 | 89.40% |
| Yes | 26 | 10.60% |
Abbreviations: IDC, Invasive ductal carcinoma; ILC, Invasive lobular carcinoma; T stage, Tumor stage; N stage, Node stage; RT, Radiotherapy; 3D CRT, 3-dimensional conformal radiotherapy; IMRT, Intensity-modulated radiation therapy; ER, Estrogen receptor; PR, Progesterone receptor, HER2, Human epidermal growth factor receptor 2.